After I tweeted about my recent post about Immunium, another Twitter user made me aware of iCancer. Why? – Because the clinical trial financed through the iCancer fundraising campaign used the Ad5PTDf35-adenovirus vector which Immunicum includes as one of their treatment platforms under development.
I thought I kick off the year with an article about Immunicum, a Swedish company I stumbled across a week or so ago. As an immunologist by training I have a soft spot for companies looking to exploit the versatility and strength of our own immune system. Immunicum does just that. In their own words, they aim to create “the […]